Following doxorubicin treatment, compared to SIRT1 ablation, SIRT1 WT complementation significantly attenuated the reduction in cell growth, whereas SIRT1 KR complementation led to only marginal attenuation of the doxorubicin-mediated reduction in cell growth, suggesting the important role of SIRT1 ISGylation in negatively regulating doxorubicin-mediated inhibition of lung cancer cell proliferation. The gene discussed is SIRT1; the disease is lung cancer.